Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo I Gordon

Showing results (11-20 of 223) with videos related to

Pageof 23
Sort By:
The Lancet. Haematology|December 25, 2025
Sequencing T-cell therapy for relapsed or refractory large B-cell lymphomaReem Karmali, Leo I Gordon
Nature Reviews. Clinical Oncology|April 18, 2013
Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathonStephane Doucet, Leo I Gordon
Cancer Biology & Therapy|January 23, 2016
Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL)Savita Bhalla, Leo I Gordon
Blood|May 5, 2012
Off-targeting oft-targeted CD20 in cHLLeo I Gordon, Richard Longnecker
Haematologica|July 18, 2024
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphomaMegan Melody, Leo I Gordon
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2011
Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenanceRupali Roy, Leo I Gordon
Expert Review of Hematology|September 14, 2016
PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacherPamela Blair Allen, Leo I Gordon
Expert Opinion on Biological Therapy|July 25, 2014
Pidilizumab in the treatment of diffuse large B-cell lymphomaLocke J Bryan, Leo I Gordon
Clinical Advances in Hematology & Oncology : H&O|May 17, 2022
CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive reviewFrédérique St-Pierre, Leo I Gordon
Seminars in Oncology Nursing|May 27, 2004
Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Mary Beth Riley, Leo I Gordon
Pageof 23

Showing results (11-20 of 223) with videos related to

Sort By:
Pageof 23
The Lancet. Haematology|December 25, 2025
Sequencing T-cell therapy for relapsed or refractory large B-cell lymphomaReem Karmali, Leo I Gordon
Nature Reviews. Clinical Oncology|April 18, 2013
Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathonStephane Doucet, Leo I Gordon
Cancer Biology & Therapy|January 23, 2016
Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL)Savita Bhalla, Leo I Gordon
Blood|May 5, 2012
Off-targeting oft-targeted CD20 in cHLLeo I Gordon, Richard Longnecker
Haematologica|July 18, 2024
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphomaMegan Melody, Leo I Gordon
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2011
Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenanceRupali Roy, Leo I Gordon
Expert Review of Hematology|September 14, 2016
PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacherPamela Blair Allen, Leo I Gordon
Expert Opinion on Biological Therapy|July 25, 2014
Pidilizumab in the treatment of diffuse large B-cell lymphomaLocke J Bryan, Leo I Gordon
Clinical Advances in Hematology & Oncology : H&O|May 17, 2022
CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive reviewFrédérique St-Pierre, Leo I Gordon
Seminars in Oncology Nursing|May 27, 2004
Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Mary Beth Riley, Leo I Gordon
Pageof 23